Business Wire

EFPIA

13.5.2022 06:02:05 CEST | Business Wire | Press release

Share
Boosting Cardiovascular Health in Europe – Towards More Resilient and Equitable Healthcare

More than two years after the COVID-19 pandemic started, healthcare systems are taking stock of the lessons learnt to strengthen their response and improve the health outcomes of patients across disease areas. In this context, the European Federation of Pharmaceutical Industries and Associations (EFPIA) CVD Network commissioned a report in collaboration with PwC on “Boosting cardiovascular health in Europe: towards more resilient and equitable healthcare” , to assess the impact of COVID-19 on cardiovascular (CVD) care and to explore possible policy actions to strengthen the healthcare systems’ response to CVDs.

The report finds that:

  • Cardiovascular disease (CVD) is the major cause of mortality and morbidity across Europe, affecting almost 95 million patients and, notably causing 1.24 million acute coronary events each year.
  • CVD accounts for almost one-third of all premature deaths and is responsible for 23 % of all disability-adjusted life years (DALYs) measured across Europe, exceeding the burden caused by all other non-communicable diseases (NCDs), including cancer.
  • At the same time, many CVDs are preventable or, at least, manageable with appropriate interventions, often more so than other major NCDs. Overall, about 70% of the CVD burden is attributable to risk factors that can be controlled or modified, such as hypertension, high cholesterol or diabetes.
  • COVID-19 has made things worse. The pandemic has increased the risk of hospitalisation and death for people with CVD and put healthcare systems under strain, disrupting detection and care pathways and exposing existing disparities in CVD care.
  • Short-term shocks, similar to the pandemic, are likely to become more frequent, thus boosting healthcare demand, and stretching healthcare services even further.
  • Evolving disease patterns will force healthcare systems to reshape their care delivery models. With 130 million Europeans expected to be over the age of 65 by 2050, CVD-related healthcare demand is bound to grow and transform over the coming decades.

Following the findings, the report offers a series of concrete policy recommendations that aim to re-design CVD care and equip European healthcare systems with the necessary tools to cope with future crises:

  • Strengthen population screening
    • Broaden screening programmes for genetic and metabolic risk factors
    • Simplify access to screening, especially for vulnerable populations
  • Ensure treatment initiation, maintenance, and follow-up for at-risk patients
    • Re-design healthcare systems to reward outcomes
    • Strengthen digital health and information sharing to improve disease management
  • Foster data-driven decision making
    • Harness the potential of data-driven solutions to inform CVD policies and support clinical decision-making and value-based care delivery

Cardiovascular diseases are Europe’s biggest health challenge. The time to act is now. Building on the available evidence, we need bold policy action for better population health in Europe ” commented Christian Thonke and Sean Lybrand, co-Chairs of the EFPIA CVD Network.

The Report calls on all CVD stakeholders to play their part in advancing CVD prevention, detection and care, by putting the spotlight on secondary prevention and encouraging a smarter use of digital technologies.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Samos Energy Acquisition Corporation Announces Pricing of Initial Public Offering10.7.2026 15:32:00 CEST | Press release

Samos Energy Acquisition Corporation (the “Company”) announced today the pricing of its initial public offering (“IPO”) of 20,000,000 units at a price of $10.00 per unit. The units will be listed on the New York Stock Exchange (the “NYSE”) and trade under the ticker symbol “SAMO.U” beginning on July 10, 2026. Each unit consists of one Class A ordinary share and one-half of one redeemable warrant, with each whole warrant entitling the holder thereof to purchase one of the Company’s Class A ordinary shares at an exercise price of $11.50 per share. Once the securities comprising the units begin separate trading, the Class A ordinary shares and warrants are expected to be listed on the NYSE under the symbols “SAMO” and “SAMO.WS,” respectively. Cantor Fitzgerald & Co. is acting as the sole book running manager for the proposed offering. The Company has granted the underwriter a 45-day option to purchase up to an additional 3,000,000 units at the IPO price. The public offering is being made

Onera hPSG® Wins Prestigious Red Dot Product Design Award10.7.2026 15:00:00 CEST | Press release

Onera Health's patch-based home polysomnography solution, Onera hPSG®, was awarded the renowned ‘Red Dot Award: Product Design 2026’ in recognition of the sensors’ innovative design, advanced functionality, and user-centric engineering. Onera Health, a leader in transforming sleep medicine, announces that its innovative product, Onera hPSG®, has been honoured with the prestigious Red Dot Product Design Award for 2026. This international recognition celebrates exceptional design quality and underscores Onera Health's commitment to excellence, creativity, and patient-centric innovation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260710266668/en/ Onera Health's patch-based home polysomnography solution, Onera hPSG®, wins Prestigious Red Dot Product Design Award 2026. The Red Dot Award, one of the most sought-after seals of quality for good design, attracted thousands of entries from around the globe. Onera hPSG® stood out f

teamLab Biovortex Kyoto Welcomes Over 1 Million Visitors within 9 Months of Opening10.7.2026 09:00:00 CEST | Press release

teamLab Biovortex Kyoto has welcomed over 1 million visitors as of July 6, 2026, 9 months after its grand opening. (*1) These visitors arrived from more than 150 countries and regions. International visitors account for approximately 42% of the total. Many of these international visitors travel from distant countries and regions, including the United States, Australia, Canada, the United Kingdom, and Germany. Approximately 30% of these international visitors purchase their tickets at least 30 days in advance. teamLab Biovortex Kyoto is teamLab's largest museum in Japan, with an average visitor stay of over two and a half hours. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260709913938/en/ teamLab Biovortex Kyoto Welcomes Over 1 Million Visitors within 9 Months of Opening *1 According to ticket purchase data from the official teamLab Biovortex Kyoto website (survey period: October 7, 2025 – July 6, 2026) Visitors Comment (M

Robbyant Launches LingBot-VA 2.0 Built Natively for Embodied AI and Physical World Control10.7.2026 08:48:00 CEST | Press release

Robbyant, an embodied AI company within Ant Group, today announced the release of LingBot-VA 2.0, the industry’s first embodied-native video-action world model. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260709654440/en/ A robot powered by LingBot-VA 2.0 engages in a real-time tabletop air hockey match with a human This release marks a key transition in robotics foundation models, shifting from repurposing digital world models to designing them natively for the physical world. Instead of relying on fine-tuned digital content generation models, LingBot-VA 2.0 is built from scratch to meet the original demands of dynamic modeling, causal prediction, and real-time execution in physical environments. Integrating world models with embodied AI has been one of the major focuses of the AI industry. However, most mainstream approaches rely on video generation models designed for digital content, which are then fine-tuned for robo

SureWerx Appoints Erik Pertot as VP/GM SureWerx EMEA10.7.2026 08:00:00 CEST | Press release

Experienced global PPE leader to strengthen portfolio strategy, operational execution, and growth across SureWerx’s international platform SureWerx, a leading global manufacturer of personal protective equipment, safety products, tools and equipment solutions, today announced the appointment of Erik Pertot as VP/GM SureWerx EMEA. Pertot will report directly to CEO Scott Dowell and will lead growth, manufacturing and M&A activities in Europe across the company’s global portfolio. Erik joins SureWerx with more than 20 years of international leadership experience across engineering, quality, marketing, sales, international supply chain, product management, and general management. He brings deep expertise in the personal protective equipment industry, with a track record of leading complex, compliance-critical programs, managing business transitions, and driving growth across multinational environments. Most recently, Pertot served as Global General Manager for Footwear and Fall Protection

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye